| 1 |
34962574 | Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. | 2022 Feb 1 |
2 |
| 2 |
33960511 | Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease. | 2021 Sep |
2 |
| 3 |
34225162 | The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. | 2021 Sep |
1 |
| 4 |
34306611 | Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors. | 2021 |
3 |
| 5 |
34346015 | Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis. | 2021 Oct |
2 |
| 6 |
31562557 | Selegiline: a molecule with innovative potential. | 2020 May |
2 |
| 7 |
32238135 | Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. | 2020 |
1 |
| 8 |
32346620 | Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. | 2020 Jun |
1 |
| 9 |
32588409 | [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease]. | 2020 Sep |
1 |
| 10 |
32703142 | Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives. | 2020 |
2 |
| 11 |
33109837 | Teleost Model as an Alternative in Parkinson's Disease. | 2020 Sep-Oct |
2 |
| 12 |
30963543 | Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. | 2019 Jul |
1 |
| 13 |
31017021 | Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status. | 2019 May |
1 |
| 14 |
31258092 | Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase. | 2019 |
2 |
| 15 |
31781365 | Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review. | 2019 |
1 |
| 16 |
29569037 | Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. | 2018 Nov |
1 |
| 17 |
29578580 | MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. | 2018 Jul |
5 |
| 18 |
29847694 | A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. | 2018 Sep |
2 |
| 19 |
30077198 | Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease. | 2018 Aug |
2 |
| 20 |
28124620 | Monoamine Oxidase B Inhibitors in Parkinson's Disease. | 2017 |
2 |
| 21 |
28294055 | Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors. | 2017 |
1 |
| 22 |
28550482 | Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. | 2017 Jun |
4 |
| 23 |
25546160 | Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study. | 2015 Feb |
1 |
| 24 |
26164425 | Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. | 2015 Jun |
1 |
| 25 |
24756517 | Pharmacological treatment of Parkinson disease: a review. | 2014 Apr 23-30 |
1 |
| 26 |
22887993 | High throughput screening to identify natural human monoamine oxidase B inhibitors. | 2013 Jun |
1 |
| 27 |
23515972 | Management of motor and non-motor symptoms in Parkinson's disease. | 2013 Apr |
1 |
| 28 |
21628600 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? | 2012 May |
1 |
| 29 |
23093014 | The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. | 2012 |
2 |
| 30 |
21939547 | Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. | 2011 Sep 22 |
2 |
| 31 |
22035027 | Diagnosis and initiation of treatment in Parkinson's disease. | 2011 |
1 |
| 32 |
22087552 | Advanced strategies for treatment of Parkinson's disease: the role of early treatment. | 2011 Oct |
1 |
| 33 |
22093536 | Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. | 2011 Dec |
1 |
| 34 |
22133327 | Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. | 2011 Dec 1 |
2 |
| 35 |
25205926 | Cell based therapies in Parkinson's Disease. | 2011 Apr |
1 |
| 36 |
20297870 | Early pharmacologic treatment in Parkinson's disease. | 2010 Mar |
2 |
| 37 |
20297872 | Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. | 2010 Mar |
1 |
| 38 |
20368333 | Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. | 2010 Jun 4 |
1 |
| 39 |
19110205 | Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. | 2009 Jan |
2 |
| 40 |
19131039 | L-dopa therapy for Parkinson's disease: past, present, and future. | 2009 Jan |
2 |
| 41 |
19259810 | Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease. | 2009 Aug |
4 |
| 42 |
18322402 | Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. | 2008 |
1 |
| 43 |
18937611 | The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. | 2008 Nov |
3 |
| 44 |
17417741 | Modification of L-DOPA pharmacological activity by MAO inhibitors. | 2007 |
2 |
| 45 |
17495756 | Advances in the pharmacologic management of early Parkinson disease. | 2007 May |
1 |
| 46 |
17186710 | Parkinson's disease: diagnosis and treatment. | 2006 Dec 15 |
1 |
| 47 |
16034956 | Monoamine oxidase B inhibitors for early Parkinson's disease. | 2005 Jul 20 |
1 |
| 48 |
16156677 | Alternatives to levodopa in the initial treatment of early Parkinson's disease. | 2005 |
2 |
| 49 |
15355491 | The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. | 2004 Oct |
3 |
| 50 |
11793163 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. | 2002 |
1 |